<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6565">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01930903</url>
  </required_header>
  <id_info>
    <org_study_id>201202</org_study_id>
    <nct_id>NCT01930903</nct_id>
  </id_info>
  <brief_title>PaneLux PTCA : Proposing an Alternative Treatment to patiEnts for Whom DES Implantation is Not Indicated, Thanks to Pantera LUX Drug Eluting Balloon</brief_title>
  <acronym>PaneLux PTCA</acronym>
  <official_title>Proposing an Alternative Treatment to patiEnts for Whom DES Implantation is Not Indicated, Thanks to Pantera LUX Drug Eluting Balloon</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik France</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biostatistics : Medpass International, 95 bis boulevard Pereire, 75017 Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Biotronik France</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The propose of this study is to demonstrate, whenever using Drug Eluting Stent is not
      possible, the clinical security at 12 months, of the combinaison Bare Metal Stent plus Drug
      Eluting Balloon.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Target Lesion Failure (TLF) at 12 months.</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>TLF is defined as a composite of cardiac death, any target vessel myocardial infarction (MI), urgent coronary artery bypass graft (CABG) and clinically driven target lesion revascularization (TLR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Failure</measure>
    <time_frame>1 and 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding rate according to BARC definition</measure>
    <time_frame>1, 6 and 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically driven target vessel revascularization</measure>
    <time_frame>1, 6 and 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACCE</measure>
    <time_frame>1, 6 and 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Cardiac death, stroke, myocardial infarction (Q wave and non Q wave) and TVR by non planned angioplasty or bypass graft</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All deaths</measure>
    <time_frame>1, 6 and 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction (MI) (Q wave and non Q wave)</measure>
    <time_frame>1, 6 and 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definite incidence of stent thrombosis</measure>
    <time_frame>1, 6 and 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically driven target lesion revascularization</measure>
    <time_frame>1, 6 and 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion failure for patients &gt;/= 80 years</measure>
    <time_frame>1, 6 and 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding rate according to BARC definition for patients &gt;/= 80 years</measure>
    <time_frame>1, 6 and 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion failure for kidney failure patients (clearance &lt; 30 ml/ min)</measure>
    <time_frame>1, 6 and 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding Rate according to BARC definition for kidney failure patients (clearance &lt; 30 ml/ min)</measure>
    <time_frame>1, 6 and 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>High Bleeding Risk Patients</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pantera Lux Drug Eluting Balloon</intervention_name>
    <description>All patients are treated with the PRO-Kinetic Energy Stent and Pantera Lux drug eluting balloon for the last post dilatation.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject has provided a written informed consent

          2. Subject &gt;/= 18 years.

          3. Patient affiliated to social security

          4. Patient acceptable candidate who accept to be contacted at different terms of
             clinical follow up (1, 6 and 12 months)

          5. Subject eligible for percutaneous coronary intervention AND undergoing a chronical
             oral anticoagulant treatment OR undergoing any semi-urgent invasive or non cardiac
             surgical planned intervention with major bleeding risks

          6. Subject eligible for Dual Anti Platelet Therapy (DAPT) of acetyl salicylic acid and
             clopidogrel for at least 3 weeks

          7. De Novo coronary lesions: &gt;/= 50% - &lt;100%

          8. Subject, vessels and target lesion eligible for angioplasty with PRO-Kinetic Energy
             stent implantation and final post-dilatation with Pantera Lux drug eluting balloon.

          9. Target lesion length &lt;/= 26 mm , visual estimation or by Quantitative Coronary
             Angiography (QCA)

         10. Reference diameters targeted vessels &gt;/=2.5mm and &lt;/= 4.0 mm (visual estimation or
             QCA)

        Exclusion Criteria:

          1. Pregnant or breast feeding females or females who intend to become pregnant during
             the time of the study

          2. Subject with a life expectancy less than 1 year

          3. Vulnerable subject, protected by law, unable to give his/her consent

          4. Subject currently enrolled in other medical or drug study and has not reached the
             primary outcome measures of that study

          5. Subject unable to be contacted for the clinical follow up at 1, 6 and 12 months

          6. Subject under chronical oral anti-coagulant treatment (optionnal indication)

          7. Subject undergoing any urgent invasive or surgical intervention with major bleeding
             risk, which can not maintain dual anti-platelet therapy (DAPT) for at least 3 weeks

          8. In stent restenotic lesion

          9. Target lesion on vessels with nominal diameter &lt; 2.5 mm

         10. Target lesion is located in or supplied by an arterial or venous bypass graft

         11. Chronical Total occlusion (CTO)

         12. Angioplasty indication for STEMI

         13. Patient with signs of cardiogenic shock

         14. Angioplasty antecedent with stent implantation (before 12 months for DES, before 6
             months for BMS)

         15. &quot;Staged procedure&quot; &gt; 8 days after the initial angioplasty

         16. Documented left ventricular ejection fraction (LVEF) &lt;/= 30%

         17. Target lesion requiring before stent implantation a device other than a
             pre-dilatation balloon (including, but not only restricted to laser, cutting balloon,
             directional coronary atherectomy, rotational atherectomy etc…)

         18. Known allergies to acetylsalicylic acid, active agent such Paclitaxel, Expicients
             like BHTC (Butiriltri-n-hexyl citrate), CoCr, Silicon Carbide.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jérôme Roncalli, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Toulouse, Hôpital Rangueil, TSA 50032, 31059 TOULOUSE Cedex 9</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie Gabillet</last_name>
    <phone>+33675547025</phone>
    <email>marie.gabillet@biotronik.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicolas Canot</last_name>
    <phone>+33146759660</phone>
    <email>nicolas.canot@biotronik.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chu Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérôme Roncalli, Prof</last_name>
      <phone>+33561323334</phone>
    </contact>
    <investigator>
      <last_name>Jérôme Roncalli, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 6, 2014</lastchanged_date>
  <firstreceived_date>August 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PRO-Kinetic Energy BMS + Pantera Lux DEB combination</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
